Spectral AI’s FDA Clearance and 2026 Revenue Timeline Clash in Earnings Call

Date of Call: Mar 24, 2026

Financials Results

• Revenue: Q4 2025 R&D revenue was $3.8 million, down from $7.6 million in Q4 2024. Full year R&D revenue decreased to $19.7 million from $29.6 million.
• EPS: Q4 2025 net income was $0.6 million or $0.02 per diluted share, compared to a net loss of $7.7 million or -$0.41 per diluted share in Q4 2024. Full year net loss was $7.6 million or $(0.29) per diluted share, compared to a net loss of $15.3 million or $(0.85) per diluted share.
• Gross Margin: Q4 2025 gross margin was 39.8%, compared to 44.0% in Q4 2024. Full year gross margin was stable at 45.4% compared to 44.9% in the prior year.

Guidance:

• Forecasting revenue of approximately $18.5 million for 2026, which includes the effect of the new BARDA funding.
• This guidance does not include any significant contributions from the sale of the VPU system.

Business Commentary:

Financial Performance and Cash Position:

• Spectral AI reported a net income of $0.6 million or $0.02 per diluted share for Q4 2025, compared to a net loss of $7.7 million or -$0.41 per diluted share in Q4 2024.
• The cash position improved to $15.4 million from $5.2 million at December 31, 2024.
• The improvement in financial performance was due to a $4 million gain in the fair value of the company’s warrant liability and reduced borrowing-related costs.

BARDA Contract and Funding:

• Spectral AI received a $31.7 million advanced funding from BARDA to accelerate and support additional features of the DeepView system.
• The contract also includes provisions for BARDA to subsidize the initial sale and distribution of up to 30 DeepView Systems in burn centers in the U.S.
• This funding is expected to expedite further development, including total body surface area measurement tool and EHR integration, and prepare for commercialization.

FDA Approval and Commercialization Strategy:

• Spectral AI is hopeful for a positive response from the FDA before the end of the second quarter of this year regarding their De Novo application for the DeepView system.
• The company plans to initiate an outcome study to measure the real-world impact of the DeepView system post-approval.
• The strategy includes expanding the sales team and engaging Deloitte Consulting to prepare for commercialization, aiming for initial sales in late 2026.

Research and Development Revenue Trends:

• Research and development revenue for Q4 2025 decreased to $3.8 million from $7.6 million in Q4 2024.
• For the full year, research and development revenue decreased to $19.7 million from $29.6 million.
• The reduction was anticipated due to the completion of the base phase under the BARDA contract and the submission of the De Novo application to the FDA.

Sentiment Analysis:

Overall Tone: Positive

• CEO states 'We are hopeful for a positive response from the FDA before the end of the second quarter of this year' and 'We believe we have a clear strategy to drive rapid market adoption'. Also notes 'We entered 2026 in the strongest liquidity and financial position in our recent history' and 'I am excited with what we have and where we’re going'.

Q&A:

• Question from Ryan Zimmerman (BTIG): How are you preparing for commercialization and what is needed to get the organization ready?
  Response: Hiring a new Chief Commercial Officer, engaging Deloitte Consulting, and expanding the sales team to be ready for sales inside and outside of BARDA in late 2026.

• Question from Ryan Zimmerman (BTIG): How does BARDA's distribution of 30 systems impact the business model and revenue?
  Response: Revenue recognition will vary by health system (purchase/lease), but it positions the company for significant installations in 2027 and 2028, with little impact expected in 2026.

• Question from Ryan Zimmerman (BTIG): What will the new BARDA funding be used for to enhance DeepView?
  Response: Label expansion, improving the total body surface area tool, EHR integration, battery life, and user interfaces to increase device value.

• Question from Carl Byrnes (Northland Capital Markets): How will the $31.7 million BARDA advance and remaining contract funds be disbursed over 2026-2028?
  Response: The advance accelerates development and commercial activities pre-approval; the full BARDA contract extends to 2030, with funding helping revenue earlier, supporting studies, label expansion, and outcome studies.

• Question from Ram Selvaraju (H.C. Wainwright): What is the timeframe for BARDA fund disbursement, approach to revising revenue guidance post-approval, and optimization outside the U.S.?
  Response: BARDA contract extends to 2030, with acceleration through 2028. Revenue guidance depends on health system deployment terms; international sales (U.K., Australia, GCC) will begin in late 2026/2027, with different revenue models.

• Question from John Vandermosten (Zacks): What does the training force look like and how will you train users?
  Response: Will expand biomedical engineer and sales staff in line with commercialization plans; the device is intuitive, and training will be provided to centers.

• Question from John Vandermosten (Zacks): How long after FDA clearance will it take to place the first units?
  Response: Hopes to place devices in late 2026, with a significant pivot in 2027.

• Question from John Vandermosten (Zacks): How will R&D spend be allocated for 2027 and beyond?
  Response: Focus on label expansion (head, hands, feet) and potentially other indications like critical limb ischemia or biofilm markers; near-term priority is advancing the DeepView system.

Contradiction Point 1

FDA Clearance and First Unit Placement Timeline

Contradiction on when the first units will be placed post-FDA clearance.

John Vandermosten (Zacks) - John Vandermosten (Zacks)

2025Q4: The company hopes to place devices in late 2026, with a significant pivot in commercial activity expected in 2027. - Vincent Capone(CEO)

What is the projected training resource allocation and timeline for deploying the first DeepView units post-FDA clearance? - Ryan Zimmerman (BTIG)

20251112-2025 Q3: The company still anticipates FDA clearance in the first half of 2026 and expects the BARDA contract work to continue as planned through early 2026. - Vincent Capone(CEO)

Contradiction Point 2

2026 Revenue Cadence

Contradiction on whether 2026 will see a revenue increase or decrease.

Ryan Zimmerman (BTIG) - Ryan Zimmerman (BTIG)

2025Q4: Revenue from these installations is not expected to significantly contribute in 2026 but will be substantial in 2027 and 2028. - Vincent Capone(CEO)

How are you preparing for commercialization as you transition to a commercial organization, and how should investors assess the commercial activity generated from the 30 BARDA-subsidized DeepView systems distributed to U.S. burn centers? - Ryan Zimmerman (BTIG)

20251112-2025 Q3: 2026 is projected to be a down year for revenue compared to 2025, though current forecasts show it may be relatively flat with a small reduction. - Vincent Capone(CEO)

Contradiction Point 3

FDA Clearance Timeline

Contradiction on certainty and timing of FDA clearance for DeepView.

Ram Selvaraju (H.C. Wainwright) - Ram Selvaraju (H.C. Wainwright)

2025Q4: The initial installations are expected to occur in late 2026, with software licensing and maintenance driving a stacking revenue effect in 2027–2028. - Vincent Capone(CEO)

What is the full disbursement timeline for the BARDA contract, how will you revise revenue guidance upon FDA licensure, and how will you optimize value outside the U.S.? - Ryan Benjamin Zimmerman (BTIG, LLC)

2025Q2: Expect clearance in the first half of next year (2026), though there is no guarantee. - Dr. Michael DiMaio(CEO)

Contradiction Point 4

BARDA Rollout Specifics

Contradiction on willingness to provide specifics about BARDA's post-approval rollout role.

Ryan Zimmerman (BTIG) - Ryan Zimmerman (BTIG)

2025Q4: The company envisions a 3-year contract model that includes software licensing and device maintenance. Revenue from these installations is not expected to significantly contribute in 2026 but will be substantial in 2027 and 2028. - Vincent Capone(CEO)

As you transition to a commercial organization, how are you preparing for commercialization, and how should investors evaluate the commercial activity generated from the 30 BARDA-subsidized DeepView systems distributed to U.S. burn centers? - Carl Edward Byrnes (Northland Capital Markets)

2025Q2: Declined to provide specifics or forward-looking predictions about BARDA's actions. BARDA's contract includes language about helping with rollout, but the company is being cautious and not speculating on the details or timing, as it is a forward-looking matter. - Dr. Michael DiMaio(CEO)

Contradiction Point 5

BARDA Contract Disbursement and Revenue Recognition Timeline

Contradiction on when revenue from BARDA will be recognized.

Ryan Zimmerman (BTIG) - Ryan Zimmerman (BTIG)

2025Q4: Revenue from these installations is not expected to significantly contribute in 2026 but will be substantial in 2027 and 2028. - Vincent Capone(CEO)

As you transition to a commercial organization, how are you preparing for commercialization, and how should investors assess the commercial activity from the 30 BARDA-subsidized DeepView systems distributed to U.S. burn centers? - Ryan Zimmerman (BTIG)

2025Q1: The strong start to the year... The second half of 2025 is expected to have less BARDA contract revenue as development... continues. - Vincent Capone(CEO)